Spectazole Related Published Studies
Well-designed clinical trials related to Spectazole (Econazole)
Econazole-polycarbophil, a new delivery system for topical therapy: microbiological and clinical results on vaginal candidiasis. [2008.06]
A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. [2003.10]
Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. [2000.12]
A comparative clinical evaluation of econazole nitrate, miconazole, and nystatin in the treatment of vaginal candidiasis. [2000.01]
Econazole and clotrimazole in the treatment of vaginal candidiasis: a double blind comparative study. [1994.09]
Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. [1991]
A comparison of butoconazole nitrate cream with econazole nitrate cream for the treatment of vulvovaginal candidiasis. [1990.09]
The antibacterial efficacy of econazole nitrate in interdigital toe web infections. [1990.04]
Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. [1988.01]
Well-designed clinical trials possibly related to Spectazole (Econazole)
Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. [2006.06]
Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh. [1998.08]
Anti-inflammatory activity of antifungal preparations. [1997.10]
[Comparison of various types of imidazole derivatives for treatment of filamentous fungal keratitis] [1996.07]
Study on the sensitizing capacity of the new antimycotic sertaconazole in the treatment of cutaneous mycoses. [1992.05]
Evaluation of skin irritation and contact sensitizing potential of fenticonazole. [1990.03]
In vitro and in vivo cutaneous penetration and antifungal activity of naftifine. [1989.10]
Other research related to Spectazole (Econazole)
Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. [2008.08]
Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. [2008.02]
Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. [2007.08]
Near infrared spectrometry for the quantification of human dermal absorption of econazole nitrate and estradiol. [2007.01]
A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. [2006.11]
Concurrent use of 5% natamycin and 2% econazole for the management of fungal keratitis. [2004.11]
A population-based case-control teratological study of vaginal econazole treatment during pregnancy. [2003.12.10]
Hepatoprotective and therapeutic effects of tetramethylpyrazine on acute econazole-induced liver injury. [2002.06]
Light and electron microscopic findings in a model of human cutaneous candidosis based on reconstructed human epidermis following the topical application of different econazole formulations. [1999]
Control of Candida albicans murine vaginitis by topical administration of polycarbophil-econazole complex. [1998.09]
Other possibly related research studies
Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. [2005.09.14]
[Antifungal drug susceptibility of Candida causing oropharyngeal candidiasis in HIV infected patients] [2001]
Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: I. Analyses of a unique database. [2004.06]
Poliosis associated with treatment of fungal endophthalmitis. [2004.12]
Dermatophyte-related granular parakeratosis. [2004.02]
Enlarging pigmented patches on the hand. [2003.10]
A pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ influx and IL-2 production in T lymphocytes. [2003.05.01]
Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay. [2002.08]
Effect of commercial ethanol propolis extract on the in vitro growth of Candida albicans collected from HIV-seropositive and HIV-seronegative Brazilian patients with oral candidiasis. [2002.03]
[New developments in medical mycology] [2001.02]
[The chemotherapy of Chagas disease] [1999]
Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity--drug supersaturation, toxicity on TR146 cells and release from a delivery system. [1999.11]
In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. [1999.07]
One-day therapy for vaginal candidiasis. A review. [1999.06]
Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drugs. [1999.03.29]
A model of human cutaneous candidosis based on reconstructed human epidermis for the light and electron microscopic study of pathogenesis and treatment. [1998.05]
Effects of nitric oxide synthase inhibition in lipopolysaccharide-induced sepsis in mice. [1998.11]
Successful management of Aspergillus scleritis by medical and surgical treatment. [1998]
The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. [1998.03]
Vulvar vestibulitis in the north of Sweden. An epidemiologic case-control study. [1997.03]
New combination for the therapy of canine otitis externa. I. Microbiology of otitis externa. [1997.02]
Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. [1996.04]
A new method of antibiotyping yeasts for subspecies discrimination and distribution in human clinical specimens. [1996.02]
Pityrosporum (Malassezia) folliculitis in Saudi Arabia--diagnosis and therapeutic trials. [1995.09]
Contact allergy to imidazoles used as antimycotic agents. [1995.08]
[Prophylaxis of puerperal infections using the Gyno-Pevaryl 150 preparation] [1995.02]
Mycotic keratitis: susceptibility to antiseptic agents. [1995]
Toxicity of antibiotics and antifungals on cultured human corneal cells: effect of mixing, exposure and concentration. [1995]
Endothelin-induced activation of neutrophil migration. [1994.08.30]
An outbreak of tinea corporis gladiatorum on a high school wrestling team. [1994.08]
Multicenter evaluation of ATB fungus: a standardized micromethod for yeast susceptibility testing. [1994.07]
Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. [1994.07]
Mycotic keratitis--an underestimated mycosis. [1994]
Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. [1993.04]
Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. [1993.03]
Widespread Candida folliculitis in a nontoxic patient. [1992.04]
Can proctological procedures resolve perianal pruritus and mycosis? A prospective study of 23 cases. [1992.02]
Mechanisms of thrombocytopenia in the acute phase of antigen-induced arthritis in rabbits. [1991.12]
The in vitro activity of terconazole against yeasts: its topical long-acting therapeutic efficacy in experimental vaginal candidiasis in rats. [1991.10]
Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent. [1991.01]
In vitro and in vivo candicidal activities of 2-(p-n-hexylphenylamino)-1,3-thiazoline. [1991]
Biochemical basis for the activity and selectivity of oral antifungal drugs. [1990.09]
In vitro antifungal activities of new imidazole salts towards dermatophytes. [1990.05]
Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. [1989.08]
Blastomycosis. [1989.04]
[Fungal otitis in Libreville. Study of 83 cases] [1989]
[Local therapy of pityriasis versicolor with 3 imidazole derivatives--results of a therapeutic study. Studies of the rate of recurrence] [1988.12.15]
Antifungal susceptibility testing of Trichosporon beigelii to imidazole compounds. [1988.07]
Itraconazole in the treatment of acute vaginal candidiasis. [1988.02.06]
Tinea of the face caused by Trichophyton rubrum with histologic changes of granuloma faciale. [1988.02]
Sulconazole. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. [1988.02]
Contact allergy to imidazole antimycotics. [1988.02]
Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics. [1988]
[Contact allergies to antifungal agents] [1987.12.15]
Activity of terbinafine in experimental fungal infections of laboratory animals. [1987.10]
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. [2006.08]
The potential of azole antifungals against latent/persistent tuberculosis. [2006.05]
What is the best way to treat tinea cruris? [2006.03]
[Congenital cutaneous candidiasis: a case report and review] [2005.12]
Discontinued drugs in 2005: anti-infectives. [2007.01]
Contact dermatitis to a canine anti-dandruff shampoo. [2007.02]
Antifungal effect of eugenol and nerolidol against Microsporum gypseum in a guinea pig model. [2007.01]
Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. [2007.09]
Medical interventions for fungal keratitis. [2008.01.23]
Fungal keratitis in London: microbiological and clinical evaluation. [2007.10]
[Tinea nigra palmaris: a clinical case in Argentina] [2007.10]
|
